NEW YORK, May 22- Little known biotechnology company Merrimack Pharmaceuticals Inc has quietly built a large pipeline of experimental cancer treatments that it aims to deliver at a fraction of the cost spent by larger rivals. Medicare system contending with new cancer treatments that can exceed $100,000 per patient.
CHICAGO, April 17- In a move to shore up its lead in Alzheimer's diagnostics, Eli Lilly and Co on Wednesday said it will acquire two imaging agents from Siemens designed to light up brain deposits of tau, an Alzheimer's protein linked with cell death. Terms of the deal with the conglomerate's Siemens Medical Solutions USA unit were not disclosed.
*Research sheds light on breast, prostate, ovarian cancer. LONDON, March 27- New research has nearly doubled the number of genetic variations implicated in breast, prostate and ovarian cancer, offering fresh avenues for screening at-risk patients and, potentially, developing better drugs.
Feb 15- A 75- year-old Indiana grain farmer will take on global seed giant Monsanto Co at the U.S. Supreme Court next week in a patent battle that could have ramifications for the biotechnology industry and possibly the future of food production.
*U.S. Supreme Court to consider same issue in April. CANBERRA, Feb 15- An Australian court ruled on Friday that two technology companies could hold a patent on genetic material related to cancer, in a case similar to one before the U.S. Supreme Court that has implications for gene-based medicine worldwide.
*KDDI lifts full-year earnings forecast. *HSBC cuts Japan rating, BNP sees index rising to 13,000.
DuckDuckGo CEO Gabriel Weinberg says web traffic on his search engine, billed as an alternative to Google that doesn't store your private information, surged 33 percent after the NSA news broke. Weinberg discusses the model of his search engine, and how the company makes money.
Wednesday, 19 Jun 2013 | 6:31 AM ETJohn Silvia, Wells Fargo Securities, and Barbara Marcin, Gabelli Dividend Income Fund, discuss whether investors should reconsider allocating their portfolios as the Fed wraps up its two-day policy meeting.
Wednesday, 19 Jun 2013 | 8:53 AM ETKen Langone, Invemed Associates chairman and president, called Fed Chairman Ben Bernanke a "lame duck."